Please login to the form below
rheumatoid arthritis
This page shows the latest rheumatoid arthritis news and features for those working in and with pharma, biotech and healthcare.
Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19
Olumiant is already approved for use as a treatment for rheumatoid arthritis, and is a one of a group of anti-inflammatory drugs that have been studied as potential COVID-19
Latest news
-
Q&A: Kate Callan
It was a combination of a great team and clients, and getting to collaborate closely with really amazing patient advocates living with rheumatoid arthritis.
-
Homesick
And then we have a whole ‘other’ group – patients with psoriasis, rheumatoid arthritis, Crohn’s disease, and also oncology patients.
-
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
and rheumatoid arthritis drug Olumiant (baricitinib).
-
Sanofi doses first patient in global Kevzara COVID-19 trial
Both Roche and Sanofi/Regeneron’s drugs are already approved for the treatment of rheumatoid arthritis, but have been repurposed after their potential against COVID-19 was first discovered earlier this
-
FDA approves Roche’s Actemra COVID-19 trial
It was first cleared by the FDA as a treatment for rheumatoid arthritis and has also subsequently been approved in juvenile idiopathic arthritis, giant cell arteritis and CRS associated with
More from news
Approximately 56 fully matching, plus 433 partially matching documents found.
Latest Intelligence
-
AI: the smart money is on the smart thinking
Take, for example, the case of baricitinib, originally an Eli Lilly rheumatoid arthritis drug, now repurposed as a promising treatment for COVID-19.
-
Cortellis Drugs to Watch in 2020 report
Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... of the JAK family of kinases leads to an aberrant production
-
20 for 2020 – Five pharma leaders to watch in 2020
to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others. ... filgotinib for rheumatoid arthritis.
-
Will biosimilars ever catch on in the US?
So, for example, AbbVie applied for 247 new patents for adalimumab and was granted 132, even though no significant changes had been made to the rheumatoid arthritis drug.
-
European biotech: a new generation of leaders emerges
is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis.
More from intelligence
Approximately 0 fully matching, plus 40 partially matching documents found.
Latest appointments
-
Portland Health appoints Jamie Hewitt as an account director
He joins the firm from the National Rheumatoid Arthritis Society, where he was its head of government affairs, leading the policy and public affairs functions. ... During his time at the National Rheumatoid Arthritis Society, Hewitt ran UK campaigns to
-
Liberation Unlimited promotes Vicky Smith
oncology, rheumatoid arthritis and eye health.
-
Galapagos appoints Bart Filius as chief financial officer
His vast experience in big pharma and his sharp strategic view will help us bring Galapagos to the next level, as we prepare to have our rheumatoid arthritis molecule GLPG0634 enter
-
TiGenix appoints Dr Marie Paule Richard
In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is
-
Liberation promotes Danielle Smith to account director
Meanwhile, Vicky joined Liberation last year and in her new role will continue to work across a range of therapeutic areas including men's health, rheumatoid arthritis and eye health.
More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Lucid Group reaches the finals of the PM360 2020 Trailblazer Initiative Awards
Lucid Group has been named as a finalist in the PM360 2020 Trailblazer Initiative Awards in the HCP Education category, for the program LiBRA 2019: Looking beyond the joint in rheumatoid ... arthritis (RA): Is there a missing link in RA management?
-
Lucid Group scoop a win and a high commendation at Communiqué 2020
Its programme – ‘LiBRA 2019: Looking beyond the joint in rheumatoid arthritis (RA): Is there a missing link in RA management?’ – won the category, with a high commendation going to ‘CLEAR HORIZONS – ... We were thrilled that our work in both
-
Lucid Group are shortlisted in three categories for Communiqué 2020
LiBRA 2019: Looking beyond the joint in rheumatoid arthritis (RA): Is there a missing link in RA management?
-
RWE Blog 1: Real-world challenges and real-world data
Studies in other disease areas, including rheumatoid arthritis, diabetes and psoriasis, support the idea that using products in the real world is different to that in clinical studies.
-
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient. Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at twelve of the key indices captured in Therapy Watch data. Click here
More from PMHub
Approximately 8 fully matching, plus 19 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- Send Us a Message
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Keytruda doubles five-year survival rate in NSCLC
- Researchers call on Pfizer to delay COVID-19 vaccine application
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Covid-19 redefines rules of customer engagement
- Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
- Aurora extends exclusive collaboration with Patient Intelligence Panel (PIP Health)
- Moderna’s COVID-19 vaccine generates strong immune response in older adults
- Regeneron’s COVID-19 antibody cocktail reduces viral load and alleviates symptoms
- What makes a great launch leader and launch team?
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Covid-19 redefines rules of customer engagement
- Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
- Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
- Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
- The concordance conundrum: understanding the complexities of behaviour change
- Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
Quick links
Infographics
